Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.44 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.41 |
| ▸ | F3 | P13726 | 6/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6805030 | 0.92 | F2 (0.44) | — | |
| SCHEMBL6801209 | 0.86 | CFD (0.47) | KMT2A | |
| SCHEMBL6808033 | 0.83 | LMNA (0.52) | KMT2AMEN1ANO1ALDH1A1POLB | |
| SCHEMBL6808403 | 0.79 | TP53 (0.45) | KMT2APOLBHTT | |
| SCHEMBL6808849 | 0.75 | BAZ2B (0.42) | — | |
| SCHEMBL6804794 | 0.74 | F10 (0.59) | KMT2AMEN1ALDH1A1POLBHTT | |
| SCHEMBL2943705 | 0.70 | BAZ2B (0.47) | KMT2AMEN1F3 | |
| SCHEMBL5171111 | 0.69 | BAZ2B (0.50) | KMT2APARP1 | |
| SCHEMBL5524698 | 0.67 | KMT2A (0.71) | KMT2AMEN1PARP1PARP10PARP14 | |
| SCHEMBL30716404 | 0.67 | KMT2A (0.71) | KMT2AMEN1PARP1PARP10PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | claimed |
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092517-A1 | Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours | RCOR3, F2, NCOR2 | KMT2A 3435/4885MEN1 3442/4885PARP1 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.